SCM
YMAB

Scopia Capital Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Scopia Capital Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-920,282
Closed -$24.1M – 27
2019
Q1 		$24.1M Sell
920,282
-667,284
-42% -$14.7M 0.89% 20
2018
Q4 		$31.3M Hold
1,587,566
– – 1.06% 21
2018
Q3 		$42.2M Buy
+1,587,566
New +$40.4M 0.81% 28

Other funds holding YMAB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Scopia Capital Management's YMAB Position: Q2 2019 in Review

Scopia Capital Management sold out of Y-mAbs Therapeutics (YMAB) in Q2 2019, closing a stake of 920,282 shares — an estimated $24.1M sold.

Scopia Capital Management first reported a position in YMAB in Q3 2018 and held it in 3 quarters. The position peaked at $42.2M in Q3 2018. 59 funds tracked by Wall St. Rank hold YMAB as of Q2 2019.

  • Scopia Capital Management reported no remaining Y-mAbs Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Scopia Capital Management sold 920,282 Y-mAbs Therapeutics shares in Q2 2019, an estimated $24.1M.
  • Scopia Capital Management first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 3 quarters.
  • Scopia Capital Management's Y-mAbs Therapeutics position peaked at $42.2M in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q2 2019.

Based on Scopia Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.